Pegvisomant
- Generic Name
- Pegvisomant
- Brand Names
- Somavert
- Drug Type
- Biotech
- CAS Number
- 218620-50-9
- Unique Ingredient Identifier
- N824AOU5XV
- Background
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
- Indication
Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
- Associated Conditions
- Acromegaly
Effect of DPP4 Inhibition on Growth Hormone Secretion
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 44
- Registration Number
- NCT01701973
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Acromegaly Combination Treatment Study
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 76
- Registration Number
- NCT01538966
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT01278342
- Locations
- 🇮🇹
Novarts Investigative Site, Naples, Italy
🇨ðŸ‡Novartis Investigative Site, Lausanne, Switzerland
Tissue Biomarker for Pegvisomant Action
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01261000
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT01181973
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
- Conditions
- Colorectal NeoplasmsLung NeoplasmsBreast NeoplasmsProstatic NeoplasmsSarcoma
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00976508
- Locations
- 🇩🇪
Pfizer Investigational Site, Muenster, Germany
The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons
- Conditions
- Interaction Between the GH/IGF-I System and the Immune-system
- Interventions
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2009-09-01
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT00969644
- Locations
- 🇩🇰
Department of Endocrinology J 106, Herlev Hospital, Herlev, Denmark
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 251
- Registration Number
- NCT00658879
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
- Conditions
- AcromegalyInsulin ResistanceImpaired Glucose Tolerance
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 18
- Registration Number
- NCT00652379
- Locations
- 🇩🇰
Department of Endocrinology, Aarhus University Hospital, Aarhus C, Aarhus, Denmark
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00642720
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.